This article discusses the research-grade synthetic peptides Semaglutide, Tirzepatide, and Retatrutide, highlighting their receptor profiles and applications in laboratory studies. Each peptide’s structural features, intended research contexts, and regulatory considerations are outlined, emphasizing that they are not approved for human or therapeutic use and are solely for scientific research.
Tirzepatide and Retatrutide represent two of the most significant multi-agonist peptides in current metabolic research. As Australian laboratories intensify their focus on obesity, diabetes, and metabolic disorders, understanding the differences between these compounds is essential for designing effective experiments. This comprehensive comparison examines the science, mechanisms, and research applications of Tirzepatide and Retatrutide, with insights